Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05308225 · ClinicalTrials.gov registry record · Phase 1
Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Sorrento Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 3
- Study locations
NCT05308225 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Sorrento Therapeutics. The registered enrollment target is 72 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT05308225, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Sorrento Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.
Conditions Studied
Interventions
- BIOLOGICAL STI-6129
Study Locations (3)
New York
- NYU Lagone Health - New York
- Columbia University Medical Center - New York
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05308225
The ClinicalTrials.gov registry entry for NCT05308225 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (87% lower). The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which STI-6129 is the first listed.
NCT05308225 reports 3 study locations spanning 2 distinct geographic areas - top geographies include New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05308225 about?
NCT05308225 is a clinical study titled "Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma". This is a two-stage phase 1b/2a, open-label, multicenter, dose-escalation study of STI-6129 administered intravenously once in a 4-week cycle in subjects with relapsed or refractory multiple myeloma.
What is the current status of trial NCT05308225?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-02-01. Estimated completion is 2026-07.
What conditions does trial NCT05308225 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05308225?
The interventions under investigation include: STI-6129 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05308225?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05308225 being conducted?
This trial has 3 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.